Neuroendocrine signaling represents a critical yet often overlooked dimension of neurodegeneration in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). These peptide-based communication systems modulate sleep-wake cycles, energy homeostasis, stress responses, social cognition, and autonomic function—all of which are profoundly disrupted in tauopathies.
The orexin system consists of orexin-A (hypocretin-1) and orexin-B (hypocretin-2), derived from the prepro-orexin precursor encoded by the HCRT gene. Orexin neurons are localized exclusively in the lateral hypothalamus and project widely to wake-promoting nuclei including the locus coeruleus (noradrenergic), dorsal raphe (serotonergic), tuberomammillary nucleus (histaminergic), and ventral tegmental area (dopaminergic) 1.
Postmortem studies in PSP demonstrate significant orexin neuron loss (40-60% reduction) in the lateral hypothalamus, correlating with excessive daytime sleepiness observed in up to 70% of CBS/PSP patients 2. Orexin deficiency also contributes to:
| Agent | Mechanism | Evidence Level | CBS/PSP Status |
|---|---|---|---|
| Solriamfetol | Dual DAT/SERT inhibitor, promotes wakefulness | FDA approved (narcolepsy) | Case reports in PD/PSP |
| Pitolisant | Histamine H3 inverse agonist | FDA approved (narcolepsy) | Clinical trials in PD |
| Orexin-A peptide | Direct receptor agonist | Preclinical | Not yet in human trials |
Clinical Protocol: Solriamfetol 75-150 mg morning (monitor BP, weight)
| Interaction | Levodopa | Rasagiline |
|---|---|---|
| Solriamfetol | Additive hypertension risk | MAO-B + dopamine reuptake inhibition: monitor BP, avoid evening dosing |
NPY is a 36-amino acid peptide encoded by the NPY gene, widely expressed in the CNS including the hippocampus, amygdala, hypothalamus, and cortex. NPY acts through Y1, Y2, Y4, and Y5 receptors, modulating anxiety, appetite, memory, and synaptic plasticity 3.
| Agent | Mechanism | Evidence Level | CBS/PSP Status |
|---|---|---|---|
| PYY (3-36) | Y2 agonist, appetite suppression | Clinical | Not studied in tauopathy |
| NPY-based peptides | Y1/Y5 modulators | Preclinical | Research phase |
| Small molecule Y1 agonists | Neuroprotection | Preclinical | Not in clinical trials |
Clinical Protocol: Focus on lifestyle (stress reduction, exercise) to support endogenous NPY signaling
No significant interactions with levodopa/rasagiline known.
CGRP is a 37-amino acid neuropeptide with two isoforms (α-CGRP, β-CGRP) derived from the CALCA gene. CGRP is highly expressed in trigeminal ganglion, dorsal root ganglion, and throughout the CNS. It is the most potent known vasodilator and plays roles in pain transmission, migraine, and neurogenic inflammation 4.
| Agent | Mechanism | Evidence Level | CBS/PSP Status |
|---|---|---|---|
| Rimegepant | CGRP receptor antagonist | FDA approved (migraine) | Not studied in tauopathy |
| Ubrogepant | CGRP receptor antagonist | FDA approved (migraine) | Not studied in tauopathy |
| CGRP neutralizing antibodies | Block CGRP signaling | FDA approved (migraine) | Not studied in tauopathy |
Note: CGRP modulation is speculative for CBS/PSP; the elevated CSF CGRP may be a biomarker rather than therapeutic target.
| Interaction | Levodopa | Rasagiline |
|---|---|---|
| CGRP antagonists | No significant interactions | No significant interactions |
AVP is a 9-amino acid peptide synthesized in the supraoptic and paraventricular nuclei of the hypothalamus. It acts via V1a (vascular), V1b (pituitary), and V2 (renal) receptors, modulating water retention, blood pressure, social behavior, and memory 5.
| Agent | Mechanism | Evidence Level | CBS/PSP Status |
|---|---|---|---|
| Intranasal AVP | Direct CNS delivery | Phase 2 (cognitive aging) | Not studied in tauopathy |
| Desmopressin | V2 agonist, reduce nocturia | Approved | May help orthostatic hypotension |
| V1a agonists | Memory enhancement | Preclinical | Not in trials |
Clinical Protocol: Desmopressin 0.1-0.2 mg at night for nocturia (monitor sodium)
| Interaction | Levodopa | Rasagiline |
|---|---|---|
| Desmopressin | May enhance fluid retention | No significant interaction |
Oxytocin is a 9-amino acid peptide synthesized in the paraventricular and supraoptic nuclei. It acts via the OXTR receptor, modulating social cognition, trust, emotional bonding, and stress responses. Oxytocin also has peripheral effects on uterine contraction and lactation 6.
| Agent | Mechanism | Evidence Level | CBS/PSP Status |
|---|---|---|---|
| Intranasal oxytocin | Direct CNS delivery | Clinical trials (autism, social cognition) | Not studied in tauopathy |
| Carbetocin | OXTR partial agonist | Approved (postpartum) | Not studied in CNS |
| Liposomal oxytocin | Enhanced delivery | Preclinical | Research phase |
Clinical Protocol: Intranasal oxytocin 24-40 IU daily (off-label, monitor for hyponatremia)
| Interaction | Levodopa | Rasagiline |
|---|---|---|
| Oxytocin | No significant interactions | No significant interactions |
PACAP is a 38-amino acid neuropeptide (PACAP-38) encoded by the ADCYAP1 gene, with widespread CNS distribution including the hypothalamus, amygdala, hippocampus, and cerebral cortex. PACAP acts via PAC1 and VPAC1/2 receptors, mediating neuroprotection, learning, memory, and circadian regulation 7.
| Agent | Mechanism | Evidence Level | CBS/PSP Status |
|---|---|---|---|
| PACAP-38 peptide | PAC1/VPAC agonist | Preclinical | Not in human trials |
| Maxadilan | PAC1 agonist | Preclinical | Research phase |
| PACAP fragments | Peptide fragments | Preclinical | Research phase |
Note: PACAP therapy is not yet clinically available; monitor for research developments.
No known interactions with levodopa/rasagiline.
Somatostatin (SST) is a 14-amino acid peptide encoded by the SST gene, with wide CNS distribution in cortex, hippocampus, and hypothalamus. It acts via sst1-sst5 receptors, functioning as a universal "off-switch" for neurotransmitter release and inhibiting growth hormone, insulin, and glucagon 8.
| Agent | Mechanism | Evidence Level | CBS/PSP Status |
|---|---|---|---|
| Octreotide | sst2/sst5 agonist | Approved (acromeggy) | Not studied in tauopathy |
| Pasireotide | sst1/2/3/5 agonist | Approved (Cushing's) | Not studied in tauopathy |
| Somatostatin analogs | Receptor modulation | Approved (various) | Limited CNS penetration |
Clinical Protocol: Octreotide 100 μg subcutaneously BID (off-label, monitor GI effects)
| Interaction | Levodopa | Rasagiline |
|---|---|---|
| Octreotide | May reduce levodopa absorption | No significant interaction |
| Component | Score | Clinical Readiness |
|---|---|---|
| Orexin/Hypocretin | 7/10 | Moderate — Solriamfetol/pitolisant available, used off-label |
| NPY | 3/10 | Low — No clear therapeutic agents |
| CGRP | 4/10 | Low — Speculative target, no tauopathy data |
| Vasopressin | 4/10 | Low — Desmopressin for symptoms, not disease modification |
| Oxytocin | 5/10 | Low-Moderate — Intranasal available off-label |
| PACAP | 2/10 | Very Low — Not clinically available |
| Somatostatin | 4/10 | Low — Octreotide available, limited CNS penetration |
Overall NET Assessment: 29/70 (41%)